Cognitive function and fatigue after diagnosis of colorectal cancer

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2404-2412

  Vardy, J ^a,b,c   Dhillon, H M ^a   Pond, G R ^d   Rourke, S B ^e,f   Xu, W ^b   Dodd, A ^b   Renton, C ^a   Park, A ^b   Bekele, T ^f   Ringash, J ^b   Zhang, H ^g   Burkes, R ^b   Clarke, S J ^a   Tannock, I F ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

^c ANZAC Research Institute   (Australia)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f ONTARIO HIV TREATMENT NETWORK   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cognitive function; Colorectal cancer; Fatigue; Quality of life; Survivorship

Indexed keywords

APOLIPOPROTEIN E4; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; D DIMER; ESTRADIOL; PROTHROMBIN;

ADULT; AGED; ANXIETY; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; COGNITIVE FUNCTION TEST; COLORECTAL CANCER; CONTROLLED STUDY; DEPRESSION; FEMALE; GLOBAL DEFICIT SCORE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; WORKING MEMORY; COLORECTAL NEOPLASMS; FATIGUE; LONGITUDINAL STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGY; YOUNG ADULT;

ADULT; AGED; COGNITION; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; YOUNG ADULT;

EID: 84936133489     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu448     Document Type: Article

References (26)

1. Schagen SB, Muller MJ, Boogerd W et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-1745.
2. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
3. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109: 1905-1913.
4. Ahles TA, Saykin AJ, McDonald BC et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152.
5. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
6. Hofman M, Ryan JL, Figueroa-Moseley CD et al. Cancer-related fatigue: the scale of the problem. Oncologist 2007; 12(Suppl 1): 4-10.
7. Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007; 21: 863-871.
8. Robbins TW, James M, Owen AM et al. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc 1998; 4: 474-490.
9. Wilson BA, Alderman N, Burgess PW et al. Behavioural Assessment of the Dysexecutive Syndrome. Edmunds, England: Thames Valley Test Company 1996.
10. Wagner L, Sweet J, Butt Z et al. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function instrument. J Support Oncol 2009; 7: W32-W39.
11. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
12. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-19.
13. Goldberg DP, Williams P. A User's Guide to the General Health Questionnaire. Windsor: NFER-Nelson Publishing Company Ltd 1991.
14. Norman MA, Moore DJ, Taylor M et al. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol 2011; 33: 793-804.
15. Heaton R, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Professional Manual. Lutz, FL: Psychological Assessment Resources 2004.
16. Carey CL, Woods SP, Gonzalez R et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004; 26: 307-319.
17. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703-708.
18. Ingraham L, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 1996; 10: 120-124.
19. Cella D, Lai JS, Chang CH et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
20. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21: 4175-4183.
21. Cruzado JA, Lopez-Santiago S, Martinez-Marin V et al. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer 2014; 22: 1815-1823.
22. Andreis F, Ferri M, Mazzocchi M et al. Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study. Support Care Cancer 2013; 21: 583-590.
23. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standarddose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100: 2292-2299.
24. Ahles TA, Saykin AJ, McDonald BC et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-4440.
25. Ahles TA, Saykin AJ, Noll WW et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12: 612-619.
26. Ganz PA, Bower JE, Kwan L et al. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 2013; 30(Suppl): S99-108.